🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Challenge

Gonorrhoea infections are escalating worldwide, with data suggesting over 82 million infections per year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts believe that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is employed against UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Data and Global Access

According to results released by a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This establishes an similar efficacy with the current standard treatment, which uses two antibiotics. The trial included nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the ability to make available and distribute the drug in a wide range of developing nations.

Medical professionals directly involved have shared optimism. Having a one-pill regimen of this kind is hailed as a "revolutionary step" for public health efforts. This is viewed as crucial to alleviate the strain of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.